# A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

> **NCT06136598** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 14 (actual)

## Conditions studied

- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** Opevesostat
- **DRUG:** Dexamethasone
- **DRUG:** Fludrocortisone
- **DRUG:** Hydrocortisone

## Key facts

- **NCT ID:** NCT06136598
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-30
- **Primary completion:** 2026-03-09
- **Final completion:** 2026-03-09
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06136598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06136598, "A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06136598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*